Healthcare -
Medical - Healthcare Plans - NASDAQ - US
$ 4.08
0.246 %
$ 2.04 B
Market Cap
-21.47
P/E
1. INTRINSIC VALUE
Balance Sheet
Clover Health Investments, Corp.
| Current Assets | 428 M |
| Cash & Short-Term Investments | 243 M |
| Receivables | 114 M |
| Other Current Assets | 71.5 M |
| Non-Current Assets | 143 M |
| Long-Term Investments | 120 M |
| PP&E | 8.46 M |
| Other Non-Current Assets | 14.4 M |
| Current Liabilities | 261 M |
| Accounts Payable | 37.2 M |
| Short-Term Debt | 1.66 M |
| Other Current Liabilities | 222 M |
| Non-Current Liabilities | 23.2 M |
| Long-Term Debt | 3 M |
| Other Non-Current Liabilities | 20.2 M |
EFFICIENCY
Earnings Waterfall
Clover Health Investments, Corp.
| Revenue | 2.03 B |
| Cost Of Revenue | 1.78 B |
| Gross Profit | 257 M |
| Operating Expenses | 466 M |
| Operating Income | -209 M |
| Other Expenses | 4.82 M |
| Net Income | -213 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clover Health Investments, Corp.
| Net Income | -213 M |
| Depreciation & Amortization | 2.51 M |
| Capital Expenditures | -584 K |
| Stock-Based Compensation | 141 M |
| Change in Working Capital | -55.4 M |
| Others | -50.7 M |
| Free Cash Flow | -116 M |
Wall Street Analysts Price Targets
Clover Health Investments, Corp.
Wall Street analysts predict an average 1-year price target for CLOV of $3.76 , with forecasts ranging from
a
low of
$1.8 to a high of $6 .
CLOV Lowest Price Target
Wall Street Target
1.8 USD
-55.88%
CLOV Average Price Target
Wall Street Target
3.76 USD
-7.84%
CLOV Highest Price Target
Wall Street Target
6 USD
47.06%
4. DIVIDEND
ANALYSIS
CLOV does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Clover Health Investments, Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
1 M USD 1
3-6 MONTHS
1.03 M USD 2
6-9 MONTHS
110 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
5 months ago
Aug 09, 2024
|
Bought
1 M USD
|
Garipalli Vivek
director, 10 percent owner:
|
+ 531700
|
1.88 USD |
|
7 months ago
Jun 17, 2024
|
Bought
1 M USD
|
Garipalli Vivek
director, 10 percent owner:
|
+ 877567
|
1.14 USD |
|
8 months ago
May 16, 2024
|
Bought
15 K USD
|
Loengard Anna U
Director
|
+ 15600
|
0.96 USD |
|
8 months ago
May 16, 2024
|
Bought
1.4 K USD
|
Loengard Anna U
Director
|
+ 1485
|
0.94 USD |
|
8 months ago
May 17, 2024
|
Bought
9.3 K USD
|
Loengard Anna U
Director
|
+ 10000
|
0.93 USD |
|
10 months ago
Mar 14, 2024
|
Bought
100 K USD
|
Loengard Anna U
Director
|
+ 137000
|
0.73 USD |
|
10 months ago
Mar 14, 2024
|
Bought
9.95 K USD
|
Loengard Anna U
Director
|
+ 13625
|
0.73 USD |
|
1 year ago
Sep 06, 2023
|
Bought
13 K USD
|
Loengard Anna U
Director
|
+ 10000
|
1.3 USD |
|
1 year ago
Sep 06, 2023
|
Bought
650 USD
|
Loengard Anna U
Director
|
+ 500
|
1.3 USD |
|
1 year ago
Sep 06, 2023
|
Bought
650 USD
|
Loengard Anna U
Director
|
+ 500
|
1.3 USD |
|
2 years ago
Mar 11, 2022
|
Bought
248 K USD
|
SHAPIRO LEE
director:
|
+ 80000
|
3.1009 USD |
|
2 years ago
Mar 03, 2022
|
Bought
253 K USD
|
Clinton Chelsea
director:
|
+ 100000
|
2.5253 USD |
|
3 years ago
Nov 22, 2021
|
Bought
10 M USD
|
Palihapitiya Chamath
10 percent owner
|
+ 1739130
|
5.75 USD |
7. News
Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization
WILLMINGTON, Del., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced it has successfully deployed its Counterpart Assistant technology within Duke Connected Care (DCC), a recognized leader in accountable care and part of the prestigious Duke University Health System. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover Health”).
globenewswire.com
- 1 week ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
zacks.com
- 3 weeks ago
Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Clover Health's recent performance shows mixed results, with revenue growth but a significant share price drop, presenting a potential buying opportunity. Operational efficiency is improving, with better adjusted EBITDA and reduced net loss, indicating progress towards profitability. Wall Street remains optimistic, with positive ratings and a potential 46% upside, bolstered by a Medicare Advantage PPO plan upgrade.
seekingalpha.com
- 4 weeks ago
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Remote-First Company -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time.
globenewswire.com
- 1 month ago
Clover Health: Balancing Innovation And Challenges
Clover Health Investments shows financial progress and challenges in 2024, with a focus on innovative Medicare Advantage plans and technology-driven healthcare solutions. The company achieved a 4.0 rating for its PPO plan, indicating improved quality of care and potential for higher CMS reimbursements. Despite a slight membership decline, Clover's financial efficiency has improved, with net income losses decreasing significantly from 2022 to 2024.
seekingalpha.com
- 1 month ago
Here's Why Clover Health Investments (CLOV) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 1 month ago
5 Medical Info System Stocks to Buy for a Stable Portfolio in 2025
Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.
zacks.com
- 1 month ago
Clover Health: Buy The Dip, Reap The Rewards
Clover's 32% dip following its Q3 earnings could be an opportunity to accumulate shares. Clover continues to grow its topline and improve its bottom line performance. Clover's latest star rating upgrade to 4 stars for payment year 2026 could help it increase its market share and secure more deals for Counterpart Assistant.
seekingalpha.com
- 2 months ago
Down -26.32% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 2 months ago
Down -25.82% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
- 2 months ago
Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 2 months ago
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
zacks.com
- 2 months ago
8. Profile
Summary
Clover Health Investments, Corp. CLOV
COUNTRY
US
INDUSTRY
Medical - Healthcare Plans
MARKET CAP
$ 2.04 B
Dividend Yield
0.00%
Description
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Contact
725 Cool Springs Blvd, Franklin, TN, 37067
https://www.cloverhealth.com
IPO
Date
June 12, 2020
Employees
552
Officers
Ms. Karen Soares
General Counsel, Senior Vice President & Corporate Secretary
Ms. Rachel Fish
Chief People Officer
Mr. Peter J. Kuipers
Chief Financial Officer
Mr. Derrick L. Nueman
Head of Investor Relations & Corporate strategy
Ms. Wendy Richey
Chief Compliance Officer
Mr. Brady Priest J.D.
Chief Executive Officer of Home Care
Ms. Jamie L. Reynoso
Chief Executive Officer of Medicare Advantage
Mr. Andrew Toy
Co-Founder, Chief Executive Officer & Director
Mr. Conrad Wai
Chief Technology Officer
Mr. Vivek Garipalli
Co-Founder & Executive Chairman